Caidya, a leading global mid-sized clinical research organization (CRO), today announced it has raised $165 million in strategic growth investment from Rubicon Founders, a U.S.-based healthcare investment firm focused on building transformational companies. This funding will propel Caidya’s next phase of growth, supporting organic expansion, strategic acquisitions, and global operations.
Rubicon Founders’ investment positions Caidya for accelerated growth, enhancing its ability to deliver cutting-edge clinical research solutions. David M. Glaccum, partner at Rubicon Founders, will join Caidya’s board of directors.
Advancing Healthcare Innovation
With a strategic footprint in 23 countries, Caidya partners with biopharma sponsors to bring innovative therapies to patients in need. The company specializes in oncology, hematology, rare and pediatric diseases, and other therapeutic areas with unmet medical needs. Its white-glove services, agile partnership model, and customized solutions have solidified its position as a trusted partner in the biopharma industry.
“This investment is a testament to our progress since the 2021 merger of dMed and Clinipace, which launched Caidya,” said Dr. Lingshi Tan, Executive Chairman of the Board. “Rubicon Founders’ support will help us achieve new milestones in advancing healthcare innovation and improving patient outcomes.”
Strategic Growth and Expansion
The $165 million investment will enable Caidya to explore strategic acquisitions, expand its operational capabilities, and strengthen its presence across the Americas, Europe, and the Asia-Pacific region. The company plans to enhance its infrastructure to meet the growing demand for its specialized services in oncology and other therapeutic areas.
Barbara Lopez Kunz, Chief Executive Officer of Caidya, expressed enthusiasm for the partnership, stating, “Rubicon Founders brings unparalleled expertise and resources to accelerate our mission. Together, we will advance healthcare innovation, making a lasting impact in the global biopharma space.”
Investor Perspective
“We are thrilled to partner with Caidya’s exceptional management team and investors,” said David M. Glaccum, partner at Rubicon Founders. “Caidya’s commitment to innovation and its proven ability to bring therapies to patients make it a leader in the global CRO space. We are excited to contribute to their growth journey.”
A Trusted Partner in Clinical Research
Caidya delivers comprehensive clinical trial services, from regulatory strategy and submissions to post-approval surveillance. Its data-driven approach ensures efficiency and quality across the drug development lifecycle. By leveraging its expertise and global network, Caidya provides biopharma sponsors access to diverse patient populations, enabling life-changing therapies to reach those in need.
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.